Efficacy of sorafenib therapy without antiviral therapy in terms of hepatitis B virus reactivation rate in patients with advanced hepatocellular carcinoma

Trial Profile

Efficacy of sorafenib therapy without antiviral therapy in terms of hepatitis B virus reactivation rate in patients with advanced hepatocellular carcinoma

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Nov 2017

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Hepatocellular carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Nov 2017 New trial record
    • 24 Oct 2017 Results presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top